Ignite Creation Date:
2025-12-24 @ 2:43 PM
Ignite Modification Date:
2026-02-25 @ 8:59 PM
Study NCT ID:
NCT02298959
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-11-17
First Post:
2014-11-21
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
Sponsor:
National Cancer Institute (NCI)
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Clinical Stage IV Cutaneous Melanoma AJCC v8 | View |
| None | Metastatic Colorectal Carcinoma | View |
| None | Metastatic Malignant Solid Neoplasm | View |
| None | Metastatic Melanoma | View |
| None | Metastatic Ovarian Carcinoma | View |
| None | Metastatic Renal Cell Carcinoma | View |
| None | Platinum-Resistant Ovarian Carcinoma | View |
| None | Recurrent Melanoma | View |
| None | Recurrent Renal Cell Carcinoma | View |
| None | Refractory Melanoma | View |
| None | Refractory Renal Cell Carcinoma | View |
| None | Sarcoma | View |
| None | Stage IV Colorectal Cancer AJCC v8 | View |
| None | Stage IV Ovarian Cancer AJCC v8 | View |
| None | Stage IV Renal Cell Cancer AJCC v8 | View |
Keywords: